SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1561214
Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren's syndrome
Provisionally accepted
Xiao Zheng
Xuexiao ChenJiaoyang DiGuimin Zheng
Wei LinXiaoran Ning
Yixuan LiuJingjing CaoXuemei ZhangFang Li*- Hebei General Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To methodically assess the effectiveness and safety of rituximab in treating primary Sjögren's syndrome.Methods: The search included databases such as PubMed, Embase, the Cochrane Library, and Web of Science, covering the period from the beginning until December 2023. A meta-analysis was conducted using Stata 14.0 software.Results: Five randomized controlled trials (RCTs) with a total of 340 patients were incorporated. The meta-analysis revealed that the group treated with rituximab had significantly lower scores in ESSPRI，pain VAS ,serum IgG levels and The blood B cell level was significantly reduced, demonstrating superior results compared to the control group. However, the treatment did not effectively reduce the ESSDAI score, stimulated and unstimulated salivary flow rates and Schirmer's test results. However, it did lead to a reduction in RF levels and enhanced complement C4 were not statistically different from the values in the control group. The occurrence of adverse events, such as infection, did not show a statistically significant difference between the two groups.Conclusion: Research has demonstrated that rituximab can decrease the levels of serum IgG and serum B cells in individuals with Sjögren's syndrome. Additionally, it can significantly enhance the ESSPRI score and pain VAS score in patients. However, it does not have a notable impact on glandular function. The occurrence of adverse effects was like that of the control group. Given the scarcity of research, the findings may be influenced by bias, and a substantial quantity of rigorous investigations is required to validate them.
Keywords: efficacy, primary Sjögren's syndrome, rituximab, Safety, Treatment
Received: 15 Jan 2025; Accepted: 16 May 2025.
Copyright: © 2025 Zheng, Chen, Di, Zheng, Lin, Ning, Liu, Cao, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fang Li, Hebei General Hospital, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.